Production of lentiviruses displaying ''early-acting'' cytokines for selective gene transfer into hematopoietic stem cells
- PMID: 18470641
- DOI: 10.1007/978-1-60327-248-3_7
Production of lentiviruses displaying ''early-acting'' cytokines for selective gene transfer into hematopoietic stem cells
Abstract
A major limitation of current lentiviral vectors (LVs) is their inability to govern efficient gene transfer into quiescent cells, such as human CD34+ cells that reside in the G0 phase of the cell cycle and that are highly enriched in hematopoietic stem cells. This hampers their application for gene therapy of hematopoietic cells. We describe here novel LVs that overcome this restriction by displaying early-acting cytokines on their surface. Display of thrombopoietin, stem cell factor or both cytokines on LV surface allows high transfer into quiescent cord blood CD34+ cells. Moreover, these surface-engineered LVs preferentially transduce and promote survival of resting CD34+ cells rather than cycling cells. These novel LVs allow superior gene transfer in the most immature CD34+ cells compared to conventional LVs, even in the presence of recombinant cytokines. This is demonstrated by their capacity to promote selective transduction in long-term culture initiating cell colonies (LTC-ICs) and of long-term non-obese diabetic/severe combined immunodeficient (NOD/SCID) repopulating cells (SRCs). Here we describe the production of these "early acting cytokine" displaying vectors and the methodology to confirm the capacity of these vectors to promote selective transduction of HSCs.
Similar articles
-
Novel lentiviral vectors displaying "early-acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells.Blood. 2005 Nov 15;106(10):3386-95. doi: 10.1182/blood-2004-12-4736. Epub 2005 Aug 2. Blood. 2005. PMID: 16076865
-
In vivo gene delivery into hCD34+ cells in a humanized mouse model.Methods Mol Biol. 2011;737:367-90. doi: 10.1007/978-1-61779-095-9_15. Methods Mol Biol. 2011. PMID: 21590405
-
Highly efficient lentiviral gene transfer in CD34+ and CD34+/38-/lin- cells from mobilized peripheral blood after cytokine prestimulation.Stem Cells. 2003;21(4):472-80. doi: 10.1634/stemcells.21-4-472. Stem Cells. 2003. PMID: 12832700
-
CD34- hematopoietic stem cells: current concepts and controversies.Stem Cells. 2003;21(1):15-20. doi: 10.1634/stemcells.21-1-15. Stem Cells. 2003. PMID: 12529547 Review.
-
Adenoviral vectors for transient gene expression in human primitive hematopoietic cells: applications and prospects.Exp Hematol. 2007 Mar;35(3):343-9. doi: 10.1016/j.exphem.2006.11.004. Exp Hematol. 2007. PMID: 17309814 Review.
Cited by
-
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.Sci Transl Med. 2010 Jun 16;2(36):36ra43. doi: 10.1126/scitranslmed.3000931. Sci Transl Med. 2010. PMID: 20555022 Free PMC article. Clinical Trial.
-
Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors.Acta Naturae. 2013 Apr;5(2):7-18. Acta Naturae. 2013. PMID: 23819033 Free PMC article.
-
Recent advances in lentiviral vector development and applications.Mol Ther. 2010 Mar;18(3):477-90. doi: 10.1038/mt.2009.319. Epub 2010 Jan 19. Mol Ther. 2010. PMID: 20087315 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical